Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 and 1/2020
Company release
Nanoform Finland Plc
March 12, 2024
18.00 Finnish time / 17.00 Swedish time
Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 and 1/2020
Helsinki, Finland – A total of 11,200 Nanoform Finland Plc’s (the “Company” or “Nanoform“) new shares has been subscribed for with the Company's stock options 1/2019 and 1/2020 by 5 March 2024. The entire subscription price for subscriptions made with the stock options of EUR 12,705 will be entered in the Company’s reserve for invested unrestricted equity. After the trade registration the total amount of shares is 78,445,164. The shares subscribed for under the stock options are expected to be registered in the Trade Register on or about 21 March 2024, as of which date the new shares will establish shareholder rights. The shares will be traded on the NASDAQ Helsinki Plc’s First North Growth Market Finland marketplace together with the old shares on or about 22 March 2024.
For further information, please contact:
Peter Hänninen, General Counsel
+358 50 353 0408
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit http://www.nanoform.com
